title: Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury.
authors.affiliation: Unit of Medical Oncology.
authors.forename: F
authors.initials: F
authors.lastname: Gelsomino
authors.affiliation: Department of Medicine and Surgery Science.
authors.forename: G
authors.initials: G
authors.lastname: Vitale
authors.affiliation: Addari Institute of Oncology and Transplant Pathology, Policlinico S.Orsola-Malpighi, University of Bologna, Bologna, Italy.
authors.forename: A
authors.initials: A
authors.lastname: D'Errico
authors.affiliation: Addari Institute of Oncology and Transplant Pathology, Policlinico S.Orsola-Malpighi, University of Bologna, Bologna, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Bertuzzi
authors.affiliation: Department of Medicine and Surgery Science.
authors.forename: P
authors.initials: P
authors.lastname: Andreone
authors.affiliation: Unit of Medical Oncology.
authors.forename: A
authors.initials: A
authors.lastname: Ardizzoni
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D002761:Cholangitis / Q000139:chemically induced*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab